A comparison of the efficacy and tolerability of brimonidine and latanoprost in adults with open-angle glaucoma or ocular hypertension: A three-month, multicenter, randomized, double-masked, parallel-group trial

Clinical Therapeutics

Volumn 23, Issue 12, 2001, Pages 1969-1983

  DuBiner, Harvey B ^a   Mroz, Michael ^b   Shapiro, Aron M ^b   Dirks, Monte S ^c  

^a Clayton Eye Center   (United States)

^b Ophthalmic Research Associates Inc   (United States)

^c Black Hills Regional Eye Institute   (United States)

Author keywords

Brimonidine; Glaucoma; Intraocular pressure; Latanoprost; Response rate

Indexed keywords

BRIMONIDINE; LATANOPROST;

ADULT; AGED; ARTICLE; BURN; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG EFFICACY; DRUG TOLERABILITY; DRY EYE; EYELID EDEMA; FEMALE; HEADACHE; HUMAN; HYPEREMIA; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MAJOR CLINICAL STUDY; MALE; MEDLINE; MULTICENTER STUDY; NAUSEA; OPEN ANGLE GLAUCOMA; PATIENT SATISFACTION; PHOTOPHOBIA; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; TREATMENT OUTCOME; VISUAL DISORDER;

EID: 0035690626     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(01)80150-8     Document Type: Article

References (35)

1. The role of medical therapy in the rank order of glaucoma treatment
2. Pharmacological therapy for glaucoma: A review
3. Antiglaucoma medications: A review of safety and tolerability issues related to their use
4. Twelve-month results of an ongoing randomized trial comparing brimonidine tartrate 0.2% and timolol 0.5% given twice daily in patients with glaucoma or ocular hypertension
5. Clinical success and quality of life with brimonidine 0.2% or timolol 0.5% used twice daily in glaucoma or ocular hypertension: A randomized clinical trial
6. Effects of brimonidine on aqueous humor dynamics in human eyes
7. Preclinical evaluation of brimonidine
8. A 1-year study of brimonidine twice daily in glaucoma and ocular hypertension. A controlled, randomized, multicenter clinical trial
9. Ongoing clinical assessment of the safety profile and efficacy of brimonidine compared with timolol: Year-three results
10. Brimonidine tartrate 0.2% twice daily vs timolol 0.5% twice daily: 1-Year results in glaucoma patients
11. 2-adrenergic agonist, after four years of continuous use
12. The effectiveness and safety of brimonidine as mono-, combination, or replacement therapy for patients with primary open-angle glaucoma or ocular hypertension: A post hoc analysis of an open-label community trial
13. Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol
14. Latanoprost treatment for glaucoma: Effects of treating for 1 year and of switching from timolol
15. A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension
16. Latanoprost: Experience of 2-year treatment in Scandinavia
17. Latanoprost. Two years' experience of its use in the United Kingdom
18. Latanoprost, a prostaglandin analog, for glaucoma therapy. Efficacy and safety after 1 year of treatment in 198 patients
19. Efficacy and safety of latanoprost eye drops for glaucoma treatment: A 1-year study in Japan
20. Comparison of brimonidine with latanoprost in the adjunctive treatment of glaucoma
21. Latanoprost for uncontrolled glaucoma in a compassionate case protocol
22. Clinical experience with latanoprost: A retrospective study of 153 patients
23. The efficacy and tolerability of latanoprost in the treatment of primary open-angle glaucoma
24. The incidence and time-course of latanoprost-induced iridial pigmentation as a function of eye color
25. Cystoid macular edema and anterior uveitis associated with latanoprost use. Experience and incidence in a retrospective review of 94 patients
26. Cystoid macular edema associated with latanoprost therapy in a case series of patients with glaucoma and ocular hypertension
27. CME and anterior uveitis with latanoprost use
28. Anterior uveitis associated with latanoprost
29. The efficacy and safety of latanoprost 0.005% once daily versus brimonidine 0.2% twice daily in open-angle glaucoma or ocular hypertension
30. Evaluation and comparison between the effects on intraocular pressure and retinal blood flow of two antiglaucomatous drugs administered in monotherapy: Brimonidine and latanoprost. Preliminary results
31. Comparison of 24-hour intraocular pressure reduction with two dosing regimens of latanoprost and timolol maleate in patients with primary open-angle glaucoma
32. Effect of timolol, latanoprost, and dorzolamide on circadian IOP in glaucoma or ocular hypertension
33. Circadian variations in intraocular pressure